The Centers for Medicare & Medicaid Services on Thursday released new data on Medicare Part D prescription drugs prescribed by physicians and other health care professionals in 2013.
The Centers for Medicare & Medicaid Services on Thursday released new data on Medicare Part D prescription drugs prescribed by physicians and other healthcare professionals in 2013.
The new data, required by the Obama administration to make healthcare more transparent, contains information from over 1 million different healthcare providers who collectively prescribed approximately $103 billion in prescription drugs and supplies paid under the Part D program.
Related: Generic prices rise, but may slow
“Beneficiaries’ personal information is not available; however, it’s important for consumers, their providers, researchers, and other stakeholders to know how many prescription drugs are prescribed and how much they cost the health care system, so that they can better understand how the Medicare Part D program delivers care,” said acting CMS Administrator Andy Slavitt in a statement.
The new data characterize the individual prescribing patterns of health providers that participate in Medicare Part D for more than 3,000 different drugs. For each prescriber and drug, the dataset includes the total number of prescriptions that were dispensed, which include original prescriptions and any refills, and the total drug cost paid by beneficiaries, Part D plans, and other sources.
Related:Recent drug pricing trends - what do these mean for your formulary?
CMS created the new data set using drug claim information submitted by Medicare Advantage Prescription Drug plans and stand-alone Prescription Drug Plans. “With this data, it will be possible to conduct a wide array of prescription drug analyses that compare drug use and costs for specific providers, brand versus generic drug prescribing rates, and to make geographic comparisons at the state level,” the CMS statement said.
The new data Part D “adds to the unprecedented information previously released on services and procedures provided to Medicare beneficiaries, including hospital charge data on common impatient and outpatient services as well as utilization and payment information for physicians and other healthcare professionals”, CMS said.
CMS has set measurable goals and a timeline to move Medicare toward paying providers based on the quality, rather than the quantity, of care they give patients, according to the statement.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More